Pharmaceuticals, Biotechnology & Life Sciences

Theriva Biologics gets AEMPS clearance to launch VIRAGE2, a Phase IIa trial testing a higher‑dose oncolytic VCN‑01 combo for metastatic pancreatic cancer.

Discover MannKind Corp’s $1.4B biotech journey: from diabetes breakthroughs to market highs and lows, navigating R&D risks while pushing innovative therapies.

Explore IOL Chemicals & Pharma’s dual‑segment growth, from premium APIs to essential chemicals, and its strong market outlook in India.

Galderma Group AG shares dip as Swiss market falls, but the company’s new global skin‑quality survey and SQAS tool signal fresh growth in derm‑care and patient‑centric solutions.

Discover how Eli Lilly’s partnership with DKSH will expand its Hong Kong and Macau reach, boost patient access, and drive growth in a booming Greater China market.

Biogen’s debut on the Frankfurt Stock Exchange boosts European liquidity, expands its investor base, and strengthens its global biotech strategy.

AtaiBeckley completes Phase 2b dosing of psychedelic VLS‑01, eyeing a Phase 3 MDD trial in 2027 and sparking takeover interest.

Vertex’s $10 billion acquisition of Crinetics adds the FDA‑approved acromegaly drug PALSONIFY and rare‑disease pipeline assets, boosting its endocrinology portfolio and growth outlook.

Vaxart reports 12‑month safety data for its oral COVID‑19 vaccine, confirming no serious concerns and a well‑tolerated profile across 400 participants in a Phase 2b trial.

Niagen Bioscience’s new “Buy” rating and rising option volatility point to fresh upside potential for the NAD⁺ biotech stock—watch its next move.